Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, on Converting Minimal Residual Disease in Multiple Myeloma

Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN, of the Taussig Cancer Institute, Cleveland Clinic, discusses what advanced practitioners need to understand about maintenance treatments with carfilzomib and lenalidomide, and conversion from minimal residual disease–positive to –negative in patients with newly diagnosed transplant-eligible multiple myeloma (Abstract 491).